clinical trial · NCT05369403
A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab
Eli Lilly and Company·phase3·completed·n = 86
Atopic DermatitisLebrikizumab
brief summary
The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) previously treated with Dupilumab.
started
Dec 19, 2022
primary completion
Jan 11, 2024
completion
Feb 5, 2025
last updated
Feb 25, 2026
official title
An Open-Label Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol